Efficiency of interferon-free therapy regimens in patients with chronic hepatitis C


Makashova V.V., Ponezheva Zh.B.

Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being, Moscow, Russia
The paper gives data on the efficiency of interferon-free antiviral therapy regimens in patients with chronic hepatitis C. It analyzes the literature sources containing the results of clinical trials of different treatment regimens, clinical practice guidelines, as well as the existing opportunities and prospects of current treatments in primary patients and patients unresponsive to the standard antiviral therapy.
Keywords: viral hepatitis C, direct-acting antivirals, antiviral therapy
Read entire article

Literature

  1. Chulanov V., Zhdanov K , Kersey K , Zhu Y , Svarovskaуa E , Massetto B , et al. Sofosbuvir plus Ribavirin for the treatment of Russian patients with chronic HCV genotype 1 or 3 Infection. Hepatology 2014; 60(Suppl 1): 676A.
  2. [Recommendations for the diagnosis and treatment of adult patients with hepatitis C]. Мoscow, 2014. (In Russ.). DOI: http://arvt.ru/sites/default/files/rf-recom-gep-C-2014.pdf
  3. Ponezheva Zh.B., Semenova I.V. [Interferon-free HCV therapy]. Lechaschiy vrach 2017; (2) https://www.lvrach.ru/2017/02/ 15436659/. (In Russ.).
  4. Yuschuk N.D, Klimova E.A., Znoyko O.O., Karetkina G.N., Maksimov S.L., Maev I.V. [Viral hepatitis. Clinic, diagnostics, treatment]. 2nd edition. Мoscow: GEOTAR-Media, 2015. 302 с. (In Russ.).
  5. EASL Recommendations on Treatment of Hepatitis C 2016. J. Hepatol. 2017; 66: 153–94.
  6. Recommendations for Testing, Managing, and Treating Hepatitis C. Changes made April 12, 2017. http://www.hcvguidelines.org
  7. Bourliere M., Sukowski M.S., Omata M. et al. An intergratted salety and efficacy analysis of > 500 pacients with compensated cirhosis treated with lediprasvir/sofosbuvir with orwithout ribaviri. Hepatology 2014; 60: 239A.
  8. Kowdley K.V., Gordon S.C., Reddy K.R., Rossaro L., Bernstein D.E., Lawitz E. et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N. Engl. J. Med. 2014; 370(20): 1879–88.
  9. Welzel T., Petersen J., Herzer K., Ferenci P., Gschwantler M., Cornberg M., et al. Daclatasvir plus sofosbuvir with or without ribavirin for treatment of chronic HCV infection in patients with advanced liver disease: results of a European compassionate use program. J. Hepatol. 2016; 64 (Suppl 2): S825.
  10. Sulkowski M.S., Gardiner D.F., Rodriguez-Torres M., Rajender R.K., Hassanein T., Jacobson et al. Daclatasvir plus Sofosbuvir for Previously Treated or Untreated Chronic HCV Infection. N. Engl. J. Med. 2014; 370: 211–21.


About the Autors

For correspondence:
Prof. Vera V. Makashova, MD; Leading Researcher, Central Research Institute of Epidemiology, Russian Inspectorate for the Protection of Consumer Rights and Human Well-Being
Address: 3a, Novogireevskaya St., Moscow 111123, Russia
Telephone: +7(495) 365-05-90
E-mail: veramakashova@yandex.ru
Information about the authors:
Zhanna B. Ponezheva, MD; Leading Researcher, Clinical Department of Infectious Diseases, Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being; Moscow, Russia; e-mail: doktorim@mail.ru


Similar Articles

Back to Content

Бионика Медиа